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Abstract
An imbalance in bone formation relative to bone resorption results in the net bone loss in 
osteoporosis and inflammatory bone diseases. While it is well known how bone resorption is 
stimulated, the molecular mechanisms that mediate impaired bone formation are poorly 
understood. Here we show that the time- and stage-specific inhibition of endogenous IκB kinase 
(IKK)/nuclear factor-kappa B (NF-κB) NF-κB in differentiated osteoblasts significantly increases 
trabecular bone mass and bone mineral density without affecting osteoclast activities in young 
mice. Moreover, the inhibition of IKK/NF-κB in differentiated osteoblasts maintains bone 
formation, thereby preventing osteoporotic bone loss induced by ovariectomy (OVX) in adult 
mice. The inhibition of IKK/NF-κB enhances the expression of Fra-1, an essential factor for bone 
matrix formation in vitro and in vivo. Taken together, our results suggest that targeting IKK/NF-
κB may help to promote bone formation in the treatment of osteoporosis and other bone diseases.
Postnatal skeletal growth and bone remodeling are highly coordinated processes that are 
primarily mediated by bone-forming osteoblasts and bone-resorbing osteoclasts1-3. To 
maintain normal bone homeostasis, bone resorption is delicately balanced with bone 
extracellular matrix deposition or bone formation, ensuring that new bone is generated 
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where old bone is removed1,4-6. Sex steroid deficiency following menopause is a frequent 
cause of osteoporosis that is characterized by trabecular bone loss and increased risk of 
fracture. Osteoporosis is the most common metabolic bone disease and a leading cause of 
morbidity and mortality in our aging population. It is commonly believed that bone 
formation is significantly impaired in osteoporosis which is partially responsible for a net 
bone loss7-11. Also, bone formation is substantially compromised in inflammatory bone 
diseases such as arthritis and periodontitis8. Thus, understanding how the function of 
differentiated or mature osteoblasts is regulated in postnatal life is important for developing 
novel and improved strategies for treating osteoporosis and inflammatory bone diseases.
The transcription factor nuclear factor kappa B (NF-κB) plays a critical role in inflammation 
and immune responses12-16. Growing evidence suggests that NF-κB signaling may be 
associated with metabolic diseases such as cachexia and diabetes17-19. The inhibition of 
IKKβ by specific peptides suppressed inflammatory bone loss by inhibiting osteoclast 
formation in an arthritis model, suggesting that NF-κB is an important target for the 
treatment of inflammatory bone diseases18. However, although the actions of NF-κB on 
osteoclastogenesis are well-understood19, little is currently known about possible actions of 
NF-κB on osteoblast activity and bone formation, especially at the stage of postnatal skeletal 
growth and bone remodeling. In this study, we found that NF-κB activation in differentiated 
osteoblasts has an anti-anabolic effect on bone formation. We uncovered that NF-κB is a 
critical factor responsible for impaired bone formation in osteoporosis. The specific 
inhibition of NF-κB in differentiated osteoblasts significantly prevented bone loss in 
ovariectomized (OVXed) mice by maintaining bone formation.
RESULTS
Inhibition of NF-κB in mature osteoblasts promotes postnatal bone formation in vivo
Our initial study was to investigate whether NF-κB also regulates osteoblast differentiation 
of mesenchymal cells since NF-κB was found to play an essential role in 
osteoclastogenesis19. Using two different NF-κB inhibitors, the dominant negative mutant 
of IKK-γ (IKK-DN or IKKγC417R) and super-repressor of IκBα (SR-IκBα)20-24, we 
found that the inhibition of NF-κB enhanced osteoblastic differentiation of mesenchymal 
C2C12 cells in vitro (Supplementary Fig. S1). Skeletal growth and bone remodeling are 
dynamic processes in postnatal life1,2,25. While significant progress has been made in 
understanding the molecular control of osteoblast differentiation during embryonic 
development, how the function of mature osteoblasts in postnatal life is regulated is not well 
studied. Due to cell heterogeneity, it is very difficult to distinguish whether NF-κB affects 
osteoblast differentiation or function in vitro. Since gene ablation of major IKK/NF-κB 
components in mice results in an embryonic lethality, it is impossible to use these mice to 
examine the role of NF-κB in bone formation in various bone disease models. Based on our 
results from mesenchymal cells, we took advantage of the osteoblast-specific bone gamma-
carboxyglutamate protein 2 (Bglap2) promoter which has been shown to be specifically 
activated in mature or differentiated osteoblasts and to be inactive in osteoblast 
progenitors26-28. Our strategy was to use the Bglap2 promoter to drive IKK-DN in mature 
osteoblasts so that we could address whether NF-κB regulates mature osteoblast function 
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without affecting osteoblast differentiation. We generated an IKK-DN construct under the 
control of the Bglap2 promoter. As expected, this construct was active in ROS17/2.8 
osteoblast-like osteosarcoma cells, but was inactive in 293T cells. As a positive control, 
CMV-driving IKK-DN was expressed in 293T cells (Fig. 1a). Subsequently, we utilized this 
construct to generate Bglap2-IKK-DN transgenic mice. Southern blot analysis revealed six 
founders expressing the transgene (Fig. 1b). One of the founders which expressed multiple 
copies of IKK-DN (Fig. 1b, lane 3) died shortly after birth. We maintained and utilized two 
different transgenic mouse lines (TG1 and TG2) for further experiments. We detected IKK-
DN proteins in transgenic mice in bone extracts, but not in other tissues including brain, 
liver, and muscle (Fig. 1c). Moreover, we isolated calvarial cells from two transgenic mouse 
lines. While IKK-DN could not be detected in freshly isolated calvarial cells, IKK-DN was 
induced in cells from Bglap2-IKK-DN mice after 2 weeks, but not in cells from wild type 
littermates (WT; Fig. 1d). Not surprisingly, as shown in Fig. 1e, the Bglap2-IKK-DN mouse 
had a phenotypically normal skeleton at birth. Histological sections also confirmed that both 
Bglap2-IKK-DN mice and WT mice had normal bone structures (data not shown).
To examine whether the inhibition of NF-κB affected postnatal bone formation, we followed 
mouse skeletal growth of two transgenic founder lines by microradiography and μCT. X-ray 
showed that the size of Bglap2-IKK-DN mice has not significantly different from that of 
wild type mice (data not shown). However, μCT analysis of the secondary spongiosa of 
distal femur metaphyses revealed that the bone mineral density (BMD) in the trabecular 
bone of Bglap2-IKK-DN mice was significantly increased compared with control mice at 
the age of 2 and 4 weeks, but not 2 and 6 months (Fig. 2a and b). Similarly, bone volumes 
(BV/TV) were also increased in Bglap2-IKK-DN mice compared with control mice at the 
age of 2 and 4 weeks, but not 2 and 6 months (Fig. 2a and b). However, there was no 
significant difference in cortical bone volume between the two groups (data not shown). 
Histological analysis of femurs and von Kossa staining of tibiae confirmed that the 
trabecular bone areas were significantly increased in 2-week-old Bglap2-IKK-DN mice 
compared with WT mice (Fig. 2c and d), suggesting that the inhibition of NF-κB enhances 
osteoblast function. The number of osteoblasts was similar in both Bglap2-IKK-DN mice 
and control mice, indicating that the inhibition of NF-κB in mature osteoblasts does not 
affect osteoblast differentiation (Fig. 2e). To further confirm that increased BMD was due to 
enhanced osteoblast function, we performed dynamic histomorphometric analysis over a 7-
day period using calcein labeling, a well-known marker of bone formation. The bone 
formation rate in 2-week-old Bglap2-IKK-DN mice (477 ± 89 μm3/μm2/year) was a 1.6-fold 
increase than that in control WT mice (299 ± 59 μm3/μm2/year) (Fig. 2f). Real-time RT-
PCR revealed that the levels of bone matrix genes including Col1α1, Col1α2, Ocn, and Ibsp 
were increased in bone extracts of 2- or 4-week-old Bglap2-IKK-DN mice (Fig. 2g). To 
examine whether the inhibition of NF-κB in differentiated osteoblasts affected osteoclast 
indirectly, we performed tartrate-resistant acid phosphatase (TRAP) assay. The number of 
osteoclasts was similar in both Bglap2-IKK-DN mice and WT mice (Fig. 2h). The level of 
serum TRAP5b, a sensitive marker of bone resorption and osteoclast function8,11, was 
similar in both mice (Fig. 2i), suggesting that the inhibition of NF-κB in mature osteoblasts 
does not affect osteoclast activation and bone resorption. Additionally, we also used the 2.3-
kilobase Col1α1 promoter to drive IKK-DN expression in early differentiated osteoblasts in 
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mice (Col1α1-IKK-DN mice). Like Bglap2-IKK-DN mice, BMD and trabecular bone 
formation in young mice were also significantly enhanced as determined by μCT and 
histological analysis (Supplementary Fig. S2). Taken together, these results suggest that the 
inhibition of NF-κB in differentiated osteoblasts promotes bone formation in young mice.
IKK/NF-κB inhibition increases bone formation in a cell-autonomous manner
To specifically determine if the inhibition of NF-κB enhanced bone-forming activity of 
osteoblasts by a cell-autonomous effect, we isolated primary calvarial cells from both 
Bglap2-IKK-DN mice and WT mice. TNF induced similar kinetics of IκBα phosphorylation 
and degradation in newly-isolated calvarial cells from Bglap2-IKK-DN and WT mice (Fig. 
3a). To determine whether IKK-DN blocked NF-κB in differentiated osteoblasts, we grow 
cells in differentiation-inducing medium for 10 days and then treated with TNF. Western 
blot confirmed that the expression of IKK-DN was induced in differentiated osteoblasts 
(Fig. 3b). While TNF induced phosphorylation and degradation of IκBα in WT cells, these 
events were significantly inhibited in differentiated Bglap2-IKK-DN cells (Fig. 3b). 
Additionally, the phosphorylation of p65 at Ser536, a well-known site of IKKβ action21 was 
also significantly inhibited (Fig. 3b). Electrophoretic mobility shift assay (EMSA) and 
Western blot analysis also confirmed that the induction of IKK-DN inhibited the nuclear 
translocation of the NF-κB induced by TNF in Bglap2-IKK-DN cells (Fig. 3c,d). The super-
shift assay demonstrated that NF-κB-binding activities in differentiated osteoblasts mainly 
consisted of p65 and p50 (Fig. 3d). Moreover, we found that osteoblast differentiation 
induced NF-κB binding activity in both Bglap2-IKK-DN cells and WT cells to a similar 
degree at the early time points. However, NF-κB binding activity were suppressed in 
Bglap2-IKK-DN cells 2 weeks after the induction of differentiation, validating that IKK-DN 
inhibited NF-κB in differentiated osteoblasts (Fig. 3e). NF-κB binding activity in 
differentiated osteoblasts did not contain c-Rel and RelB (Supplementary Fig. S3). Upon 
induction of differentiation, bone matrix mineralization was more dramatically enhanced in 
Bglap2-IKK-DN cells compared to that in WT cells (Fig. 3f). Consistently, Real-time RT-
PCR revealed that the expression of Runx2 and Sp7 was increased in Bglap2-IKK-DN cells. 
The induction of Ocn and Ibsp was significantly higher in Bglap2-IKK-DN cells than in WT 
cells (Fig. 3g). In contrast, the expression of Tnfsf11 and Tnfrsf11b which controls osteoclast 
formation in these cells were not changed in Bglap2-IKK-DN cells compared with control 
cells (Fig. 3h). Additionally, we also isolated primary calvarial cells from both Col1α1-IKK-
DN mice and WT mice. We found that calvarial cells isolated from Col1α1-IKK-DN mice 
also displayed enhanced bone matrix gene expression and bone mineralization compared 
with WT cells (Supplementary Fig. S4).
To further rule out a possible non-specific effect of IKK-DN, we also over-expressed p65 to 
determine whether NF-κB activation could reverse the effect of IKK-DN on osteoblast 
function. p65 is the active subunit of NF-κB which is located at the downstream of the IKK 
activation site12-16. If IKK-DN promoted bone formation through inhibiting NF-κB, the 
over-expression of p65 should be able to reverse IKK-DN-mediated enhancement. Using 
retroviral infection, we stably expressed p65 in Bglap2-IKK-DN cells as determined by 
Western blot analysis. The over-expression of p65 strongly suppressed matrix mineralization 
in Bglap2-IKK-DN cells (Fig. 3i). Real-time RT-PCR also confirmed that the over-
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expression of p65 inhibited the expression of Runx2, Sp7, Alp, Ocn, Ibsp, and Col1α2 (Fig. 
3j). On the contrary, over-expression of c-Rel and RelB in calvarial cells could not inhibit 
osteoblast differentiation and mineralization (Supplementary Fig. S5).
The inhibition of NF-κB reduces bone loss induced by ovariectomy
The elevated pro-inflammatory cytokines in osteoporosis have been found to stimulate bone 
resorption and inhibit bone formation8,30. Since these cytokines potently activate NF-κB, 
based on our results described above, we hypothesized that NF-κB activation secondary to 
sex steroid deficiency might inhibit osteoblast function in osteoporosis. To mimic the 
molecular pathogenesis of bone loss in postmenopausal osteoporosis in humans, the OVX 
mouse model has been widely used to induce estrogen deficiency and bone loss. Since the 
bone structure and bone mineral density of adult Bglap2-IKK-DN mice were identical to 
WT mice, these mice serve as an excellent model to test whether NF-κB activation 
promoted bone loss by inhibiting osteoblast function in a definitive fashion.
We sham-operated or OVXed both 3-month-old WT mice and Bglap2-IKK-DN mice from 
two founder lines. μCT revealed that trabecular bones in vertebrae and femurs from WT 
mice were significantly lost after OVX compared with sham-operated mice. In contrast, far 
less bone loss was observed in Bglap2-IKK-DN mice after OVX (Fig. 4a,b). Quantitative 
measurements indicated that whereas approximately 40% of BMD was lost in WT mice 
after OVX, only 12% BMD was lost in trabecular bone of femurs in Bglap2-IKK-DN mice 
after OVX (Fig. 4c). In vertebrae, while BMD was reduced over 40% in WT mice, BMD 
was only reduced by 20% in Bglap2-IKK-DN mice (Fig. 4d). Similarly, the loss of bone 
volume was also significantly prevented in Bglap2-IKK-DN mice compared with WT mice 
after OVX (Fig. 4c,d). Histological analysis also revealed that, while the trabecular bone 
mass was dramatically depleted in WT mice, a significant amount of the trabecular bone was 
retained in the bone marrow cavity of Bglap2-IKK-DN mice after OVX (Fig. 4e). To further 
confirm our results, we also performed OVX in Col1-IKK-DN mice. Compared with WT 
mice, bone loss in Col1-IKK-DN mice was also significantly reduced (Supplementary Fig. 
S6). Finally, we found that, while TNF inhibited bone formation induced by bone 
morphogenetic proteins (BMP) in WT mice, TNF inhibition of bone formation in Bglap2-
IKK-DN mice was significantly reduced (Supplementary Fig. S7).
NF-κB activation inhibits bone formation in osteoporosis
To explore the molecular mechanism by which the inhibition of NF-κB prevented bone loss 
in osteoporosis, we first examined whether NF-κB was activated in osteoporosis using the 
specific NF-κB antibodies to detect the active form of p6523. Using anti-HA antibodies, we 
detected IKK-DN expression in osteoblasts of Bglap2-IKK-DN mice, but not of WT mice 
(Fig. 5a). While the active p65 in mature osteoblasts stained very weakly in Bglap2-IKK-
DN mice, intensive p65 staining in mature osteoblasts was detected in WT mice after OVX. 
As a point of comparison, the active p65 was not stained in sham-operated mice (Fig. 5a).
To examine whether the inhibition of NF-κB enhanced osteoblast activity, we measured the 
levels of serum osteocalcin (Ocn) at 0, 1, 2, 4, 6 and 8 weeks after OVX. While a substantial 
increase in the levels of serum Ocn in both WT and Bglap2-IKK-DN mice was induced 1 to 
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4 weeks after OVX, an even greater increase in the levels of serum Ocn was observed in 
Bglap2-IKK-DN mice (Fig. 5b). The levels of serum Ocn remained significantly higher in 
Bglap2-IKK-DN mice than that in WT mice 8 weeks after OVX (Fig. 5b). Moreover, in 
vivo dynamic labeling revealed that bone formation rates 4 weeks after OVX were 
significantly higher in Bglap2-IKK-DN mice than those in WT mice (Fig 5c). Histological 
analysis showed that the inhibition of NF-κB in mature osteoblasts did not affect osteoblast 
differentiation (Fig. 5d). There were no differences in osteoclast numbers between WT and 
Bglap2-IKK-DN mice after OVX (Fig. 5e). Moreover, the levels of serum Trap5b were 
increased at similar rates in WT and Bglap2-IKK-DN mice after OVX (Fig. 5f).
The inhibition of NF-κB promotes bone formation by up-regulating JNK/Fra-1
To explore the molecular mechanism through which NF-κB inhibition enhanced bone 
formation, we screened multiple signaling pathways that are involved in bone matrix protein 
deposition. We found that JNK activity in Bglap2-IKK-DN cells was greater than WT cells 
two weeks after induction of osteoblast differentiation in vitro (Fig. 6a, second panel). The 
appearance of increased JNK activities was consistent with the induction of IKK-DN (top 
panel). In contrast, there were no significant differences in p38 activities between Bglap2-
IKK-DN and WT cells (Fig. 6b). Previously, NF-κB was found to negatively regulate JNK 
activity, and inhibition of NF-κB leads to prolonged JNK activation31-33. Thus, increased 
JNK activities were likely due to the inhibition of NF-κB in differentiated osteoblasts.
It is known that the activation of JNK stimulates AP-1 transcription7,34. Genetic studies 
established that several members of AP-1 family members such as Fra-1 (encoded by Fosl1) 
and FosB play essential roles in bone formation after birth35-37. Thus, we first explored 
whether Fosl1 and Fosb were differentially induced in Bglap2-IKK-DN cells relative to WT 
cells. Real-time RT-PCR revealed that Fosl1 expression was significantly higher in Bglap2-
IKK-DN cells compared with WT cells upon induction (Fig. 6c). Of note, the difference 
might be underestimated due to cell heterogeneicity in vitro. In contrast, RT-PCR showed 
that there was no difference in Fosb and deltaFosb in both Bglap2-IKK-DN cells and WT 
cells (Fig. 6d). Additionally, other AP-1 family members including Jun, Junb, Jund and Fos 
were detected at similar levels in both Bglap2-IKK-DN cells and control cells (Fig. 6e). 
Moreover, Western blot analysis also confirmed that Fra-1 proteins were enhanced in 
Bglap2-IKKDN cells compared with control cells (Fig. 6a). The JNK inhibitor SP600125 
also inhibited the expression of Fra-1, suggesting that Fra-1 expression was dependent on 
JNK activation (Fig. 6f).
To determine if Fra-1 played a role in osteoblast function, we utilized a siRNA strategy to 
knock-down Fosl1. While shRNA Fosl1-1 reduced Fra-1 levels by only 20%, shRNA 
Fosl1-2 reduced over 90% of Fra-1 levels in osteoblasts as determined by Western blot 
analysis (Fig. 6g). Consistently, shRNA Fosl1-2 more significantly inhibited bone matrix 
mineralization of Bglap2-IKK-DN cells in vitro (Fig. 6h). Real-Time RT-PCR revealed that 
shRNA Fosl1-2 substantially suppressed the expression of bone matrix genes including Ocn, 
Ibsp, and Col1α2 (Fig. 6i). To further determine whether enhanced Fra-1 expression was 
responsible for preventing bone loss in OVX mice, we also performed immunostaining to 
examine Fra-1 expression in osteoblasts in vivo. While the basal level of Fra-1 was similar 
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in both sham-operated WT and Bglap2-IKK-DN mice, the intensive Fra-1 staining was 
found in osteoblasts localized on the bone surfaces of Bglap2-IKK-DN mice relative to WT 
mice after OVX (Fig. 6j).
DISCUSSION
Post-menopausal osteoporosis is a common debilitating metabolic disease that represents a 
major public burden to human health. There is a relative deficit in bone formation in 
osteoporosis. In this study, NF-κB is identified as a critical factor responsible for inhibiting 
bone formation in a model of osteoporosis. The suppression of NF-κB in differentiated 
osteoblasts prevents osteoporotic bone loss by maintaining osteoblast function. Considering 
the well-established role of NF-κB in osteoclast activation and bone resorption, our results 
suggest that targeting NF-κB in the treatment for osteoporosis and inflammatory bone 
disorders will not only suppress bone resorption, but also promote bone formation which is 
important for rebuilding bone mass.
According to our immunostaining studies, NF-κB in differentiated osteoblasts is abnormally 
activated in OVX-induced osteoporosis. There are two primary mechanisms which may 
promote NF-κB activation in differentiated osteoblasts. First, estrogen receptor (ER) has 
been found to directly inhibit NF-κB transcription in a ligand-dependent fashion by 
interacting with NF-κB38. Since ER is expressed in osteoblasts, estrogen may negatively 
regulate NF-κB activities under the physiological conditions. However, during the 
pathogenesis of osteoporosis, this negative regulation may be diminished due to lack of 
estrogen, resulting in the elevation of basal NF-κB activities in osteoblasts. Second, the pro-
inflammatory cytokines, including TNF, IL-1, IL-6 and IL-7, have been found to be highly 
expressed by T cells and other cells in osteoporosis8. These cytokines can potently stimulate 
NF-κB activities in osteoblasts. Previously, most studies focused on how pro-inflammatory 
cytokines activate NF-κB to induce osteoclast formation and activation18. However, it has 
long been known that the pro-inflammatory cytokines also inhibited osteoblast 
differentiation and bone formation in osteoporosis, arthritis, periodontitis and multiple 
myeloma by unknown mechanims8,9,30,39. Our results suggest that these cytokines activate 
NF-κB to suppress osteoblast function, thereby inhibiting bone formation. Our in vitro 
studies revealed that the inhibition of NF-κB leads to enhanced Fra-1 expression in 
differentiated osteoblasts. Previously, the loss and gain of function studies in mice have 
demonstrated that Fra-1 is an essential factor for bone matrix deposition or bone 
formation35,37. However, although Fra-1 is an important target, it remains possible that NF-
κB may regulate other molecules to inhibit bone formation. Taken together, based on our 
studies described here and other works on osteoclasts, we propose a new role of NF-κB in 
osteoporosis: the activation of NF-κB due to sex steroid deficiency not only promotes 
osteoclast activation and bone resorption, but simultaneously inhibits osteoblast function, 
thus limiting the compensatory bone formation from maintaining bone homeostasis 
(Supplementary Fig. S8).
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We isolated primary calvarial cells from new-born mice and cultured in α-MEM with 10% 
FBS. To induce osteoblastic differentiation, we grew cells in differentiation-inducing media 
containing 100 μg/ml ascorbic acid, 2 mM β-glycerophosphate and 1 μM dexamethasone for 
1, 2 and 3 weeks. After induction, we fixed cells with 70% EOTH and stained with an ALP 
staining kit according to the manufacturer’s protocol (Sigma-Aldrich). For detecting 
mineralization, we induced cells for 2 to 3 weeks, fixed with 70% ETOH and stained with 
2% Alizarin red (Sigma-Aldrich).
Western Blot Analysis, EMSA and Real-time RT-PCR
We performed Western blot analysis and EMSA as described previously23. We obtained the 
primary antibodies from the following sources: polyclonal antibody to IκBα (Santa Cruz); 
polyclonal antibody to p65 (Rockland); monoclonal antibody to α-tubulin (Sigma); and 
polyclonal antibody to Runx-2 (Oncogene Research Products). We extracted total RNA 
using Trizol (Invitrogen). We synthesized 2-μg aliquots of RNAs using random hexamers 
and reverse transcriptase (Invitrogen). We performed the Real-time PCR reactions using the 
QuantiTect SYBR Green PCR kit (Qiangen) and Icycler iQ Multi-color Real-time PCR 
Detection System. The primer sequences are listed in Supplementary Methods.
Generation of Transgenic Mice
We used the plasmid pGL647 contains the Bglap2 promoter to specifically drive osteoblast-
specific gene expression in vivo26. We subcloned human IKK-DN cDNA into pGL647. The 
fragments of Bglap2-IKK-DN transgene were purified and microinjected into (C57BL/6 X 
SJL) F2 mouse oocytes (Charles River Laboratories) and surgically transferred to 
pseudopregnant C57BL/6 dams by the University of Michigan Transgenic Animal Model 
Core. We screened the founders by PCR using mouse tail genomic DNA and confirmed 
them using Southern blot analysis. We bred two transgenic founder animals into C57BL/6 
mice for six generations to obtain a defined genetic background. We OVXed 3-month-old 
transgenic and WT mice to induce osteoporosis. 2 months after operation, we sacrificed 
mice and harvested tibiae, femurs and vertebrae for histological and μCT analysis. We 
collected blood samples and isolated serums for serology. We measured serum TRAP5b a 
mouse TRAP™ assay kit (SBA Sciences) and OCN with an OCN ELISA kit (Biomedical 
Technologies Inc.). The University Committee on Use and Care of Animals at the 
University of Michigan and/or the Animal Research Committee at the University of 
California, Los Angeles approved all mouse protocols.
Bone Histological and Morphological Analysis
We stained skeleton from newborn pups with alizarin red and alcian blue as previously 
described28. For histological analysis, we sacrificed mice at the age of 2, 4 and 8 weeks and 
6 months, and fixed femurs and vertebrae in 10% neutral buffered formalin. For 
immunostaining, we performed antigen retrieval by pressure cooking in a Decloaking 
chamber (Biocare Medical) in citrate buffer (2.1 g/L citric acid, pH 6.0) at 120 °C for 20 
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min. We incubated sections with polyclonal antibodies against Fra-1 (Santa Cruz; 1:100), 
polyclonal antibodies against the active form of p65 (Rockland Inc; 1: 100), monoclonal and 
polyclonal antibodies against HA (1:100), and polyclonal antibodies against phosphor-JNK 
(Cell Signaling; 1: 200) at 4 °C overnight. We then incubated sections with horseradish 
perioxidase-labeled polymer for 30 min, detected the immunocomplexes with AEC+ 
chromogen (Dako EnVision System) and counterstained with hematoxylin as described 
previously23. For examination of bone formation, we injected mice with calcein seven days 
apart and sacrificed two days after the final injection. We isolated tibiae, fixed them in 
ethanol, and embedded them in methyl methacrylate. We prepared 8-μm longitudinal 
sections with microtome. We evaluated sections by fluorescent microscope or stained with 
1% toluidine blue, or von Kossa reagents. For osteoclast detection, we stained the sections 
with TRAP activities using a leukocyte acid phosphatase staining kit (Sigma-Aldrich). We 
measured bone parameters of femurs, tibiae and vertebrae using computer-assisted 
histomorphometry using Image Pro Plus 4.5 (Media Cybernetics) and SPOT 4.0 software 
(Diagnostic Instruments).
We set the microradiography unit to 80 kV and 100 μA and scanned specimens at a 8.93 m 
voxel resolution on an EVS Corporation μCT scanner, with a total of 667 slices per scan. 
We generated a three-dimensional reconstruction with GEMS MicroView software from the 
set of scans. We defined the regions of interest (ROI) as the areas between 0.3 mm and 0.6 
mm proximal to the growth plate in the distal femurs in order to include the secondary 
trabecular spongiosa. In vertebral bodies, we selected a cylinder fitting in the whole central 
regions of the trabecular bone as ROI. We used a fixed threshold (600) to extract the 
mineralized bone phase and actual bone volume, and calculated BMD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Generation of transgenic mouse specifically expressing IKK-DN in differentiated 
osteoblasts
(a) Generation of Bblap2-dependent IKK DN construct. Cells were probed with anti-HA 
monoclonal antibodies. α-tubulin was used as a loading control. (b) Generation of Bblap2-
IKK-DN transgenic mice. Genomic DNAs from tail tissues were probed with 32P-labeled 
human IKK-DN cDNA probes. N, Genomic DNAs from WT mice; TG, Bblap2-IKK-DN 
transgenic mouse; 5P, 5 copies of human IKK-DN cDNA; 10P, 10 copies of human IKK-
DN cDNA. (c) IKK-DN was specifically expressed in bone tissues. Total RNA from long 
bones, brain, muscle and liver examined with RT-PCR. WT, wild type mouse; TG1, Bblap2-
IKK-DN founder line 1; TG2, Bblap2-IKK-DN founder line 2. (d) IKK-DN was induced in 
differentiated osteoblasts. Differentiated cells were probed with anti-HA antibodies. α-
tubulin was used as a loading control. TG1, Bblap2-IKK-DN transgenic mouse line 1; TG2, 
Bblap2-IKK-DN transgenic mouse line 2. (e) Normal skeleton of newborn WT and Bblap2-
IKK-DN mice. Whole mounts of newborn skeletons were stained with alcian blue and 
alizarin red. 1, whole skeleton; 2, upper extremities; 3, hind limbs; 4, Rib.
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Fig. 2. The inhibition of NF-κB by IKK-DN in mature osteoblasts enhanced bone formation in 
young mice
(a) μCT images of the trabecular bone of femurs from WT and Bblap2-IKK-DN mice. (b) 
Enhanced bone formation in young Bblap2-IKK-DN mice. Morphometric properties of 
femurs from different ages of both WT and Bblap2-IKK-DN mice were measured by μCT. 
The results are the average values from 12-15 mice per group and presented as mean ± s.d. 
**P < 0.01. BMD, bone mineral density; BV/TV, trabecular bone volume per tissue volume; 
WT, wild type mice; TG, Bblap2-IKK-DN mice. (c) H&E analysis of femurs from WT and 
Bblap2-IKK-DN mice. Scale bar, 50 μm. (d) von Kossa staining of tibiae from WT and 
Bblap2-IKK-DN mice. Scale bar, 50 μm. (e) Osteoblast numbers in both WT and Bblap2-
IKK-DN mice. The results are the average value from 12-15 mice per group and presented 
as mean ± s.d. (f) Enhanced bone formation in Bblap2-IKK-DN mice as determined by 
calcein double-labeling. Four-week-old mice were labeled with calcein. The results are the 
average value from 10 mice per group. **P < 0.01. Scale bar, 10 μm. (g) The expression of 
bone matrix genes was enhanced in young Bblap2-IKK-DN mice. Total RNAs were 
examined with Real-time RT-PCR. *P < 0.05; **P < 0.01. (h) Osteoclast numbers in both 
WT and Bblap2-IKK-DN mice. The results are the average value from 12-15 mice per group 
and presented as mean ± s.d. Oc.S/BS, osteoclast surface per bone surface; Oc.N/BPm 
(mm-1); osteoclast number per bone perimeter. ( i)Serum Trap5b in both WT and Bblap2-
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IKK-DN mice. The results are the average values from 12-15 mice per group and presented 
as mean ± s.d.
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Fig. 3. The inhibition of NF-κB in mature osteoblasts enhances bone formation in a cell-
autonomous fashion
(a) NF-κB signaling was intact in un-differentiated osteoblast progenitors. The 
phosphorylation and degradation of IκBα were examined by Western blot analysis. (b) IKK-
DN inhibited IKKβ activities in differentiated osteoblast cells isolated from Bblap2-IKK-DN 
mice. Calvarial cells were induced to differentiate for 10 days. After induction, cells were 
treated with TNF. The phosphorylation and degradation of IκBα and p65 phosphorylation 
were examined by Western blot analysis. The induction of IKK-DN was probed with anti-
IKKγ. (c) IKK-DN blocked the nuclear translocation of p65 induced by TNF. The level of 
nuclear p65 was examined by Western blot analysis. (d) IKK-DN blocked TNF-induced NF-
κB-binding activities. (e) IKK-DN blocked NF-κB in differentiated osteoblasts. Calvarial 
cells from both WT and Bglap2-IKK-DN mice were induced to differentiate for the 
indicated periods and the nuclear proteins were isolated. Nuclear proteins were 
incubated 32P-labeled κB probed. (f) The inhibition of NF-κB in differentiated osteoblasts 
enhanced mineralization. The experiments were performed in duplicate. The results 
represent average value from three independent experiments. **P < 0.01. (g) The inhibition 
of NF-κB enhanced the expression of Runx2, Sp7, Ocn and Ibsp as determined by Real-time 
RT-PCR. **P < 0.01. (h) The inhibition of NF-κB in differentiated osteoblasts did not affect 
the expression of Tnfsf11 and Tnfrsf11b. (i) Over-expression of p65 in calvarial cells 
isolated from Bglap2-IKK-DN mice inhibited mineralization. p65 was examined by Western 
blot analysis. The mineralization was examined by Alizarin red staining. (j) p65 overcame 
IKK-DN effects on bone matrix gene expression. Cells were induced to differentiate and 
total RNAs were examined by Real-time RT-PCR. *P < 0.05; **P < 0.01.
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Fig. 4. The inhibition of NF-κB in mature osteoblasts prevents trabecular bone loss induced by 
OVX in adult mice
(a) The inhibition of NF-κB prevented trabecullar bone loss of femurs in adult mice as 
determined by μCT. (b) The inhibition of NF-κB prevented trabecullar bone loss of 
vertabrae as determined by μCT. (c and d) Quantitative measurement of bone loss in 
vertebrae and femurs by μCT. The results are average values from 12-15 mice per group and 
presented as mean ± s.d. **P < 0.01. (e) The inhibition of NF-κB prevented trabecular bone 
loss of femurs as determined by the histological analysis. Scale bar, 100 μm.
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Fig. 5. The inhibition of NF-κB in mature osteoblasts prevents bone loss by maintaining 
osteoblast functions in adult mice
(a) NF-κB in osteoblasts was activated during OVX-induced bone loss. 3-month-old WT 
and Bblap2-IKK-DN mice were OVXed or sham-operated. Femurs from mice were 
sectioned and stained with anti-active form of p65 and anti-HA. Scale bars at left panel, 50 
μm; scale bars at right panel, 20 μm. (b) The inhibition of NF-κB enhanced osteoblast 
activities in osteoporosis. Serum Ocn was measured using an Ocn ELISA kit. The results are 
average values from 6-8 mice per group and presented as mean values ± s.d. *P < 0.05; **P 
< 0.01. (c) The inhibition of NF-κB enhanced bone formation in osteoporosis. The bone 
formation rate in mice was determined 4 weeks after operation. The results are average 
values from 6-8 mice per group and presented as mean values ± s.d. *P < 0.01. (d) The 
inhibition of NF-κB did not affect osteoblast numbers. Osteoblast numbers in mice were 
examined 4 weeks after operation. The results are average values from 6-8 mice per group 
and presented as mean values ± s.d. (e) The inhibition of NF-κB in osteoblasts did not affect 
osteoclast formation. Osteoclast numbers in mice were examined 4 weeks after operation. 
The results are average values from 6-8 mice per group and presented as mean values ± s.d. 
(f) The inhibition of NF-κB in osteoblasts did not inhibit bone resorption in osteoporosis. 
Mice were operated and sacrificed at 0, 1, 2, 3, 4, 6 and 8 weeks. Serum Trap5b levels were 
measured using a mouse TRAP™ assay kit. The results are average values from 6-8 mice 
per group and presented as mean values ± s.d.
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Fig. 6. The inhibition of NF-κB promoted osteoblast activities by inducing Fra-1 expression
(a) The inhibition of NF-κB enhanced JNK activities and Fra-1 expression in differentiated 
osteoblasts. Calvarial cells from both WT and Bblap2-IKK-DN mice were induced to 
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differentiate and the JNK phosphorylation and Fra-1 expression were examined by Western 
blot analysis. α-tubulin was used as a loading control. (b) The inhibition of NF-κB did not 
affect p38 activation. (c) The inhibition of NF-κB in mature osteoblasts enhanced Fosl1 as 
determined by Real-time RT-PCR. **P < 0.01. (d) The inhibition of NF-κB in mature 
osteoblasts did not affect the expression of Fosb and deltaFosb as determined by RT-PCR. 
(e) The inhibition of NF-κB in mature osteoblasts did not affect the expression of Jun, Junb, 
Jund and Fos as determined by Real-time RT-PCR. (f) The inhibition of JNK suppressed 
Fosl1. Whole cell lysates were examined by Western blot analysis. (g) The knock-down of 
Fosl1 by shRNA. Whole cell lysates were probed with anti-Fra-1 antibodies. α-tubulin was 
used as a loading control. (h) The knock-down of Fosl1 significantly decreased 
mineralization. *P < 0.05; **P < 0.01. (i) The knock-down of Fosl1 significantly reduced 
the expression of bone matrix genes. *P < 0.05; **P < 0.01. (j) The inhibition of NF-κB in 
mature osteoblasts enhanced Fra-1 expression in OVX mice. The femoral sections from WT 
and Bblap2-IKK-DN mice after OVX or sham operation were stained with anti-Fra-1 
antibodies. Scale bars, 50 μm.
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